LYON, France--(BUSINESS WIRE)--Regulatory News:
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC US: EYRYY), a French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, has received the EnterNext Tech 40 Label and announces its inclusion in the Tech 40 index.
Wanting to give more prominence to outstanding listed Tech companies, every year EnterNext grants its Tech 40 label to 40 out of over 320 small and midcap Tech companies listed on the various Euronext markets. An independent group of European experts selected the first forty on the basis of their business, financial and stock market performance.
Help employers find you! Check out all the jobs and post your resume.
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC US: EYRYY), a French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, has received the EnterNext Tech 40 Label and announces its inclusion in the Tech 40 index.
Wanting to give more prominence to outstanding listed Tech companies, every year EnterNext grants its Tech 40 label to 40 out of over 320 small and midcap Tech companies listed on the various Euronext markets. An independent group of European experts selected the first forty on the basis of their business, financial and stock market performance.
Help employers find you! Check out all the jobs and post your resume.
